yahoo_financeOriginal article
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Phase 2Halneuron®Neutral
AI Analysis
Summary
Dogwood Therapeutics announced the commencement of a Phase 2b long-term extension study for Halneuron in chemotherapy-induced neuropathic pain.
Clinical Trial Data
Phase
2b
Importance:5/10
Sentiment:
0.20
clinical_trialphase_2blong_term_extensionchemotherapy_induced_neuropathic_pain
Related Companies
Read the original article
Published by yahoo_finance on May 18, 2026 12:45 PM